Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...

Metformin, a chemical relative of that compound, has been a top type 2 diabetes treatment in the United States since it was approved in 1994. It’s cheap—less than a dollar per dose—and readily ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Meanwhile, cities in New Mexico, Minnesota, Kansas, and Utah are leading the pack for cities who are the most open to trying ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...